Search - tctmd.com

Displaying 21 - 40 of 179

Sort: Relevancy | Date

All Eyes on PCI—Should Patients’ Family Members Watch Cases?

News Opinion Conversations in Cardiology

All Eyes on PCI—Should Patients’ Family Members Watch Cases?

December 19, 2024

Reimbursement Issues Seem to Be Holding Renal Denervation Back

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

December 19, 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

October 28, 2024

Reassuring 5-Year Outcomes for Sapien-Treated TAVI Patients With Small Annuli

News Conference News NY Valves 2024

Reassuring 5-Year Outcomes for Sapien-Treated TAVI Patients With Small Annuli

Michael O'Riordan

June 05, 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

News Daily News

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

May 09, 2024

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

May 02, 2024

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

News Conference News TCT 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

Yael L. Maxwell

October 30, 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

News Conference News TCT 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

Yael L. Maxwell

October 24, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Medicare Data on AMICS Too Muddied for Firm Conclusions on Impella

News Daily News

Medicare Data on AMICS Too Muddied for Firm Conclusions on Impella

June 21, 2023

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

Large Medicare Analysis Reopens Debate Over Multivessel Revascularization

News Conference News STS 2023

Large Medicare Analysis Reopens Debate Over Multivessel Revascularization

Yael L. Maxwell

January 24, 2023

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

News Features

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

October 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.